MindMed Reports First Quarter 2024 Financial Results and Business Updates

Contributed by: Business Wire

Logo

Tags

Mental Health

Health

Neurology

Clinical Trials

Pharmaceutical

Biotechnology

Q1 2024 Financial Results

More Like This

MindMed Reports 2023 Financial Results and Business Updates

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120